Overview

* BioRestorative Q3 2025 revenue declines significantly compared to Q3 2024

* Company reports Q3 net loss of $3 mln, up from $1 mln in Q3 2024

* BioRestorative strengthens financial position with recent stock offering and private placement

Outlook

* Company focuses on near-term revenue strategy in BioCosmeceutical platform

* BioRestorative aims to expand BioCosmeceutical offerings for FDA approvals

Result Drivers

* REVENUE DECLINE - Co attributes significant Q3 revenue decline to timing of BioCosmeceutical orders

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$3 mln

Income

Q3 -$3.70

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for BioRestorative Therapies Inc ( BRTX ) is $8.00, about 82.4% above its November 11 closing price of $1.41

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)